Suppr超能文献

23810例导管原位癌的结果。

Results of 23,810 cases of ductal carcinoma-in-situ.

作者信息

Sumner William E, Koniaris Leonidas G, Snell Sarah E, Spector Seth, Powell Jodeen, Avisar Eli, Moffat Frederick, Livingstone Alan S, Franceschi Dido

机构信息

Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, Room 3550, University of Miami, Miami, Florida 33136, USA.

出版信息

Ann Surg Oncol. 2007 May;14(5):1638-43. doi: 10.1245/s10434-006-9316-1. Epub 2007 Jan 24.

Abstract

BACKGROUND

Screening mammography has increased the number of patients diagnosed with ductal carcinoma-in-situ (DCIS) in the past 20 years. The Florida Cancer Data System is the largest single source incident cancer registry in the United States. We analyzed this registry to determine the changing incidence and treatment patterns for DCIS.

METHODS

Patients with DCIS from 1981 to 2001 were identified. Age-adjusted rate, descriptive statistics, and incidence of future DCIS and invasive breast cancer were calculated.

RESULTS

A total of 23,810 DCIS patients were identified. The age-adjusted rate of DCIS has risen from 2.4 to 27.7 per 100,000 women between 1981 and 2001. Median age was 64 years; 85% of patients were white, 6.6% African American, and 7.5% Hispanic. Median tumor size was .9 cm. Forty-seven percent of patients had breast-conserving therapy (BCT). Half of the 53% of patients undergoing mastectomy underwent a modified radical mastectomy. Eight percent received no surgical treatment. Sentinel lymph node biopsy was used in 2.7% of patients who underwent a mastectomy. After BCT, 37.5% received adjuvant radiotherapy, and only 13% were treated with hormonal therapy.

CONCLUSIONS

The incidence of DCIS has risen dramatically with the advent of screening mammography. Increasing numbers of these patients are treated with BCT, although a large proportion are still treated with mastectomy, in some cases combined with axillary dissection. Sentinel lymph node biopsy and tamoxifen are important components of therapy, the use of which is slowly increasing in the treatment of DCIS.

摘要

背景

在过去20年中,乳腺钼靶筛查增加了导管原位癌(DCIS)的诊断病例数。佛罗里达癌症数据系统是美国最大的单一来源癌症发病登记处。我们分析了该登记处的数据,以确定DCIS发病率和治疗模式的变化。

方法

确定1981年至2001年期间患有DCIS的患者。计算年龄调整率、描述性统计数据以及未来DCIS和浸润性乳腺癌的发病率。

结果

共确定了23810例DCIS患者。1981年至2001年期间,DCIS的年龄调整率从每10万名女性2.4例升至27.7例。中位年龄为64岁;85%的患者为白人,6.6%为非裔美国人,7.5%为西班牙裔。肿瘤中位大小为0.9厘米。47%的患者接受了保乳治疗(BCT)。接受乳房切除术的53%患者中有一半接受了改良根治性乳房切除术。8%的患者未接受手术治疗。2.7%接受乳房切除术的患者进行了前哨淋巴结活检。接受BCT后,37.5%的患者接受了辅助放疗,仅13%的患者接受了激素治疗。

结论

随着乳腺钼靶筛查的出现,DCIS的发病率急剧上升。越来越多的此类患者接受BCT治疗,尽管仍有很大一部分患者接受乳房切除术,在某些情况下还结合腋窝清扫术。前哨淋巴结活检和他莫昔芬是治疗的重要组成部分,其在DCIS治疗中的应用正在缓慢增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验